PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) marked its first anniversary as a publicly traded company on Thursday by ringing the Nasdaq Opening Bell at the Nasdaq MarketSite in New York’s Times Square, signaling a milestone in the company’s push to advance a tightly focused clinical pipeline.
The ceremonial bell-ringing on Thursday, January 22, 2026, highlighted Medicus’ first year on the Nasdaq exchange, a period the company says has been defined by disciplined execution and a narrowed emphasis on advancing select therapeutic programs through mid-stage clinical development.
Since going public, Medicus has concentrated on moving assets through Phase 2 proof-of-concept trials while seeking licensing or strategic partnerships with larger pharmaceutical companies positioned to handle late-stage development and commercialization.
The company’s current pipeline includes SkinJect, a localized immunogenic precision therapy for basal cell carcinoma that Medicus estimates targets a $2 billion market opportunity. The portfolio also includes Teverelix, a next-generation gonadotropin-releasing hormone antagonist aimed at advanced prostate cancer patients with high cardiovascular risk and acute urinary retention relapse. Together, the programs represent an estimated $6 billion opportunity, according to the company.
“Marking one year on Nasdaq is an important milestone for Medicus,” said Raza Bokhari, the company’s executive chairman and chief executive officer. He said Medicus’ focus since becoming a public company has been on execution, with particular attention on advancing its SkinJect Phase 2 program, which is nearing database lock and an upcoming clinical data readout.
Bokhari said the anticipated results could open the door to potential partnering opportunities, adding that the company values continued shareholder support as it assembles clinical and regulatory packages aimed at therapies addressing significant unmet medical needs.
The Nasdaq appearance served as both a symbolic and strategic moment for Medicus, underscoring its ambition to translate early-stage science into partnerships and, ultimately, commercial therapies in competitive oncology markets.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.